Cargando…

Outcome of COVID-19 Infection in Patients With Multiple Sclerosis Who Received Disease-Modifying Therapies: A Systematic Review and Meta-Analysis

BACKGROUND AND PURPOSE: A systematic review and meta-analysis was performed of the outcome of Coronavirus disease 2019 (COVID-19) infection in patients with multiple sclerosis (MS) who received disease-modifying therapies (DMTs). METHODS: Relevant studies published before November 2022 in the PubMed...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Ning, Yu, WuHan, Sun, Mengjiao, Zhang, Wenjing, Zhou, Dan, Sun, Jing, Wang, ManXia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Neurological Association 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10329925/
https://www.ncbi.nlm.nih.gov/pubmed/36929061
http://dx.doi.org/10.3988/jcn.2022.0348
_version_ 1785070120427585536
author Liu, Ning
Yu, WuHan
Sun, Mengjiao
Zhang, Wenjing
Zhou, Dan
Sun, Jing
Wang, ManXia
author_facet Liu, Ning
Yu, WuHan
Sun, Mengjiao
Zhang, Wenjing
Zhou, Dan
Sun, Jing
Wang, ManXia
author_sort Liu, Ning
collection PubMed
description BACKGROUND AND PURPOSE: A systematic review and meta-analysis was performed of the outcome of Coronavirus disease 2019 (COVID-19) infection in patients with multiple sclerosis (MS) who received disease-modifying therapies (DMTs). METHODS: Relevant studies published before November 2022 in the PubMed, Cochrane Library, Chinese National Knowledge Infrastructure, and Web of Science databases were retrieved using the following search expression: (“multiple sclerosis” OR “MS”) AND (“DMT” OR “disease modifying therapies”) AND (“COVID-19”). Two authors independently screened the articles and extracted the data. Qualitative analyses and a meta-analysis constituted 22 of the 794 retrieved articles. Differences in the hospitalization and mortality rates were used as the main measures of efficacy, and the meta-analysis was performed using RevMan software. RESULTS: 22 clinical trials were selected. The hospitalization rate was lower in the 3,216 patients who received DMTs than in the 774 patients who did not receive any treatment, with a moderate effect size of 0.43 (p<0.00001). The mortality rate was also lower among patients with MS treated using DMTs than in controls (odds ratio [OR]=0.19, 95% confidence interval [CI]=0.13–0.27, p<0.00001). The hospitalization rates for COVID-19 infection in patients with MS treated with anti-CD20 therapy also increased markedly (OR=3.32, 95% CI=2.63–4.20, p<0.00001). However, there was no significant difference between patients with MS who did and did not receive DMTs. CONCLUSIONS: In summary, the application of DMTs was found to be valuable for patients with MS infected with COVID-19. However, more clinical studies are needed to determine the use of anti-CD20 drugs in patients with MS during the COVID-19 pandemic.
format Online
Article
Text
id pubmed-10329925
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Korean Neurological Association
record_format MEDLINE/PubMed
spelling pubmed-103299252023-07-11 Outcome of COVID-19 Infection in Patients With Multiple Sclerosis Who Received Disease-Modifying Therapies: A Systematic Review and Meta-Analysis Liu, Ning Yu, WuHan Sun, Mengjiao Zhang, Wenjing Zhou, Dan Sun, Jing Wang, ManXia J Clin Neurol Original Article BACKGROUND AND PURPOSE: A systematic review and meta-analysis was performed of the outcome of Coronavirus disease 2019 (COVID-19) infection in patients with multiple sclerosis (MS) who received disease-modifying therapies (DMTs). METHODS: Relevant studies published before November 2022 in the PubMed, Cochrane Library, Chinese National Knowledge Infrastructure, and Web of Science databases were retrieved using the following search expression: (“multiple sclerosis” OR “MS”) AND (“DMT” OR “disease modifying therapies”) AND (“COVID-19”). Two authors independently screened the articles and extracted the data. Qualitative analyses and a meta-analysis constituted 22 of the 794 retrieved articles. Differences in the hospitalization and mortality rates were used as the main measures of efficacy, and the meta-analysis was performed using RevMan software. RESULTS: 22 clinical trials were selected. The hospitalization rate was lower in the 3,216 patients who received DMTs than in the 774 patients who did not receive any treatment, with a moderate effect size of 0.43 (p<0.00001). The mortality rate was also lower among patients with MS treated using DMTs than in controls (odds ratio [OR]=0.19, 95% confidence interval [CI]=0.13–0.27, p<0.00001). The hospitalization rates for COVID-19 infection in patients with MS treated with anti-CD20 therapy also increased markedly (OR=3.32, 95% CI=2.63–4.20, p<0.00001). However, there was no significant difference between patients with MS who did and did not receive DMTs. CONCLUSIONS: In summary, the application of DMTs was found to be valuable for patients with MS infected with COVID-19. However, more clinical studies are needed to determine the use of anti-CD20 drugs in patients with MS during the COVID-19 pandemic. Korean Neurological Association 2023-07 2023-03-13 /pmc/articles/PMC10329925/ /pubmed/36929061 http://dx.doi.org/10.3988/jcn.2022.0348 Text en Copyright © 2023 Korean Neurological Association https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0 (https://creativecommons.org/licenses/by-nc/4.0/) ) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Liu, Ning
Yu, WuHan
Sun, Mengjiao
Zhang, Wenjing
Zhou, Dan
Sun, Jing
Wang, ManXia
Outcome of COVID-19 Infection in Patients With Multiple Sclerosis Who Received Disease-Modifying Therapies: A Systematic Review and Meta-Analysis
title Outcome of COVID-19 Infection in Patients With Multiple Sclerosis Who Received Disease-Modifying Therapies: A Systematic Review and Meta-Analysis
title_full Outcome of COVID-19 Infection in Patients With Multiple Sclerosis Who Received Disease-Modifying Therapies: A Systematic Review and Meta-Analysis
title_fullStr Outcome of COVID-19 Infection in Patients With Multiple Sclerosis Who Received Disease-Modifying Therapies: A Systematic Review and Meta-Analysis
title_full_unstemmed Outcome of COVID-19 Infection in Patients With Multiple Sclerosis Who Received Disease-Modifying Therapies: A Systematic Review and Meta-Analysis
title_short Outcome of COVID-19 Infection in Patients With Multiple Sclerosis Who Received Disease-Modifying Therapies: A Systematic Review and Meta-Analysis
title_sort outcome of covid-19 infection in patients with multiple sclerosis who received disease-modifying therapies: a systematic review and meta-analysis
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10329925/
https://www.ncbi.nlm.nih.gov/pubmed/36929061
http://dx.doi.org/10.3988/jcn.2022.0348
work_keys_str_mv AT liuning outcomeofcovid19infectioninpatientswithmultiplesclerosiswhoreceiveddiseasemodifyingtherapiesasystematicreviewandmetaanalysis
AT yuwuhan outcomeofcovid19infectioninpatientswithmultiplesclerosiswhoreceiveddiseasemodifyingtherapiesasystematicreviewandmetaanalysis
AT sunmengjiao outcomeofcovid19infectioninpatientswithmultiplesclerosiswhoreceiveddiseasemodifyingtherapiesasystematicreviewandmetaanalysis
AT zhangwenjing outcomeofcovid19infectioninpatientswithmultiplesclerosiswhoreceiveddiseasemodifyingtherapiesasystematicreviewandmetaanalysis
AT zhoudan outcomeofcovid19infectioninpatientswithmultiplesclerosiswhoreceiveddiseasemodifyingtherapiesasystematicreviewandmetaanalysis
AT sunjing outcomeofcovid19infectioninpatientswithmultiplesclerosiswhoreceiveddiseasemodifyingtherapiesasystematicreviewandmetaanalysis
AT wangmanxia outcomeofcovid19infectioninpatientswithmultiplesclerosiswhoreceiveddiseasemodifyingtherapiesasystematicreviewandmetaanalysis